Component

Human body fat mass in CLA trials

Context-specific entity; species, compartment and exposure are stated on each claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Fat mass and weight fell from baseline in the t10,c12 arm but not significantly more than placebo.

    trans-10,cis-12 conjugated linoleic acid → Human body fat mass in CLA trials source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Same 12-week trial.
    limitations
    Do not present within-group loss as superiority over placebo.
    nutrient_topic
    CLA collection; isomer, preparation, species, exposure and manipulation remain explicit. · Conjugated linoleic acid / CLA isomer family
    plain_language
    A before-and-after change was not a demonstrated treatment benefit.
    primary_references
    Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. · 2002 · https://pubmed.ncbi.nlm.nih.gov/12196420/ · DOI 10.2337/diacare.25.9.1516

    Conjugated linoleic acid: isomers, signaling, nutrient interactions and discovery (2026-09-19) · lines 422–428

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Same 12-week trial. · source_derived_draft · unverified_draft

    ## cla-human-t10-fat A before-and-after change was not a demonstrated treatment benefit. Fat mass and weight fell from baseline in the t10,c12 arm but not significantly more than placebo. Model: Same 12-week trial. Limitations: Do not present within-group loss as superiority over placebo. Evidence access: Primary abstract Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. · 2002 · https://pubmed.ncbi.nlm.nih.gov/12196420/ · DOI 10.2337/diacare.25.9.1516
    Complete structured claim and evidence

  2. At one year, body fat mass was lower than placebo in CLA-triglyceride and free-fatty-acid groups by 8.7% and 6.9%, respectively.

    Study-specific mixed-isomer CLA preparations → Human body fat mass in CLA trials source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    180 overweight adults randomized to two formulations or olive oil.
    limitations
    These are fat-mass comparisons, not percentage-point body-fat changes or proven disease prevention.
    nutrient_topic
    CLA collection; isomer, preparation, species, exposure and manipulation remain explicit. · Conjugated linoleic acid / CLA isomer family
    plain_language
    A longer mixed-preparation trial found a body-composition effect.
    primary_references
    Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. · 2004 · https://pubmed.ncbi.nlm.nih.gov/15159244/ · DOI 10.1093/ajcn/79.6.1118

    Conjugated linoleic acid: isomers, signaling, nutrient interactions and discovery (2026-09-19) · lines 454–460

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · 180 overweight adults randomized to two formulations or olive oil. · source_derived_draft · unverified_draft

    ## cla-year-fat A longer mixed-preparation trial found a body-composition effect. At one year, body fat mass was lower than placebo in CLA-triglyceride and free-fatty-acid groups by 8.7% and 6.9%, respectively. Model: 180 overweight adults randomized to two formulations or olive oil. Limitations: These are fat-mass comparisons, not percentage-point body-fat changes or proven disease prevention. Evidence access: Primary abstract Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. · 2004 · https://pubmed.ncbi.nlm.nih.gov/15159244/ · DOI 10.1093/ajcn/79.6.1118
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards